{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:15:40Z","timestamp":1787163340009,"version":"build-2736575974"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,7,15]]},"DOI":"10.2169\/internalmedicine.2236-18","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T18:07:27Z","timestamp":1553710047000},"page":"2057-2061","source":"Crossref","is-referenced-by-count":5,"title":["Disseminated Intravascular Coagulation-like Reaction after Rituximab Infusion in a Patient with Nephrotic Syndrome"],"prefix":"10.2169","volume":"58","author":[{"given":"Hiroki","family":"Nishiwaki","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Oikawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kajitani","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Komukai","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Japan"},{"name":"Division of Nephrology, Kawasaki-Saiwai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Koiwa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Engelhard M. Anti-CD20 antibody treatment of non-Hodgkin lymphomas. Clin Immunol 172: 101-104, 2016.","DOI":"10.1016\/j.clim.2016.08.011"},{"key":"2","unstructured":"2. KDIGO. clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2: 1-274, 2012."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Prytula A, Lijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25: 461-468, 2010.","DOI":"10.1007\/s00467-009-1376-6"},{"key":"4","unstructured":"4. Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6: 1308-1315, 2011."},{"key":"5","unstructured":"5. Beco A, Castro-Ferreira I, Coentrao L, et al. Rituximab for steroid dependent nephrotic syndrome. Clin Nephrol 74: 308-310, 2010."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid dependent minimal change disease. Kidney Int 83: 511-516, 2013.","DOI":"10.1038\/ki.2012.444"},{"key":"7","unstructured":"7. Francois H, Daugas E, Bensman A, et al. Unexpected efficacy of rituximab in multi-relapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 49: 158-161, 2007."},{"key":"8","unstructured":"8. Guitard J, Hebral AL, Fakhouri F, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant 29: 2084-2091, 2014."},{"key":"9","unstructured":"9. Bruchfield A, Benedek S, Hilderman M, et al. Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant 29: 851-856, 2014."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rigamonti C, Volta C, Colombi S, et al. Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. Leukemia 15: 186-187, 2001.","DOI":"10.1038\/sj.leu.2401987"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shah C, Grethlein SJ. Case report of rituximab-induced thrombocytopenia. Am J Hematol 75: 263, 2004.","DOI":"10.1002\/ajh.20028"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pamuk GE, Donmez S, Turgut B, Demir M, Vural O. Rituximab induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol 78: 81, 2005.","DOI":"10.1002\/ajh.20218"},{"key":"13","unstructured":"13. Otrock ZK, Mahfouz RA, Oghlakian GO, Salem ZM, Bazarbachi A. Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica 90 (Suppl): ECR23, 2005."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Thachil J, Mukherje K, Woodcock B. Rituximab-induced haemorrhagic thrombocytopenia in a patient with hairy cell leukaemia. Br J Haematol 135: 273-274, 2006.","DOI":"10.1111\/j.1365-2141.2006.06299.x"},{"key":"15","unstructured":"15. Larrar S, Guitton C, Willems M, Bader-Meunier B. Severe hematological side effects following Rituximab therapy in children. Haematologica 91 (Suppl): ECR36, 2006."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rosado M, Chao H, Rose M. Severe acute thrombocytopenia following rituximab therapy. Leuk Lymphoma 48: 2239-2240, 2007.","DOI":"10.1080\/10428190701625099"},{"key":"17","unstructured":"17. Dhand S, Bahrain H. Rituximab-induced severe acute thrombocytopenia: a case report and review of literature. Cancer Invest 26: 913-915, 2008."},{"key":"18","unstructured":"18. Yi JH, Kim SJ, Ahn HK, Lee SJ, Chang MH, Kim WS. Rituximab-induced acute thrombocytopenia: a case report and review of the literature. Med Oncol 26: 45-48, 2009."},{"key":"19","unstructured":"19. Ram R, Bonstein L, Gafter-Gvili A, Ben-Bassat I, Shpilberg O, Raanani P. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am J Hematol 84: 247-250, 2009."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kotsianidis I, Goutzouvelidis A, Anastasiades A, et al. Severe thrombocytopenia and fibrinolysis mimicking disseminated intravascular coagulation after rituximab infusion. Am J Hematol 85: 146, 2010.","DOI":"10.1002\/ajh.21597"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Parajuli R, Hire E, Shah BK. Rituximab-induced acute severe thrombocytopenia. Br J Haematol 149: 804, 2010.","DOI":"10.1111\/j.1365-2141.2010.08119.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Adiyodi J, Thachil J, Hawkins S, et al. Thrombocytopenia with rituximab treatment -splenomegaly as the risk factor. Ann Hematol 89: 95-96, 2010.","DOI":"10.1007\/s00277-009-0768-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Pilorge S, Park S, Dreyfus F, Bouscary D, Tamburini J. Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenstr\u00f6m macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination. Leuk Lymphoma 51: 2288-2290, 2010.","DOI":"10.3109\/10428194.2010.523127"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Novak J, Mocikova H, Pavlicek P, Gaherova L, Kozak T. Rituximab-induced coagulopathy. Leuk Lymphoma 53: 2299-2301, 2012.","DOI":"10.3109\/10428194.2012.682313"},{"key":"25","unstructured":"25. El-Osta H, Nair B. Rituximab-induced acute thrombocytopenia: an underappreciated entity. Leuk Lymphoma 54: 2736-2737, 2013."},{"key":"26","unstructured":"26. Sadashiv SK, Rao R, Fazal S, Lister J. Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 13: 602-605, 2013."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ureshino H, Nishioka A, Kojima K, et al. Rituximab-induced acute thrombocytopenia in high tumor burden follicular lymphoma. Intern Med 55: 2061-2064, 2016.","DOI":"10.2169\/internalmedicine.55.6140"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Rafei H, Nassereddine S, Garcia IF. Disseminated intravascular coagulation-like reaction following rituximab infusion. BMJ Case Rep 8: 1-6, 2017.","DOI":"10.1136\/bcr-2016-218443"},{"key":"29","unstructured":"29. Omura Y, Shimazu H, Takahashi T. Rituximab-induced acute thrombocytopenia in a patient with follicular lymphoma: a case report and review of the literature. Intern Med 57: 1151-1154, 2018."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Endo Y, Koga T, Ishida M, et al. Rituximab-induced acute thrombocytopenia in granulomatosis with polyangiitis. Intern Med 57: 2247-2250, 2018.","DOI":"10.2169\/internalmedicine.0335-17"},{"key":"31","unstructured":"31. Giezen TJ, Mantel-Teeuwisse AK, ten Berg MJ, et al. Rituximab induced thrombocytopenia: a cohort study. Eur J Haematol 89: 256-266, 2012."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/14\/58_2236-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T23:38:37Z","timestamp":1563579517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/14\/58_2236-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":31,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2236-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]}}}